*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the "**U.S. Securities Act**") or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States.*

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated October 30, 2026 (the "**Prospectus**") issued by Ganzhou Hemay Pharmaceutical Co., Ltd. (the "**Company**").*

GANZHOU HEMAY PHARMACEUTICAL CO., LTD.

贛州和美藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 0054)

ANNOUNCEMENT

UPDATE ON THE GLOBAL OFFERING

(1) POSTPONEMENT OF THE GLOBAL OFFERING AND THE LISTING
(2) REFUND OF APPLICATION MONIES
(3) NO ISSUE OF SHARE CERTIFICATES

POSTPONEMENT OF THE GLOBAL OFFERING AND THE LISTING

The Company announces that it has decided at this time to postpone the Global Offering and the Listing due to the current market conditions.

The International Underwriting Agreement relating to the International Offering will not be entered into and the Hong Kong Underwriting Agreement relating to the Hong Kong Public Offering will therefore not become unconditional.

The Company would like to express its gratitude to its prospective investors for their interest in the Company, for their support and for their positive feedback during the Global Offering.

The Company remains committed to completing the Global Offering and the Listing in due course.

REFUND OF APPLICATION MONIES

Application monies in respect of applications made through the **HK eIPO White Form** service for the Hong Kong Offer Shares (including brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%) will be refunded in full without interest.

In the case of application monies paid from a single bank account, **HK eIPO White Form** e-Auto Refund payment instructions will be dispatched to the respective application payment bank accounts on Monday, November 9, 2026. In the case of application monies paid from multiple bank accounts, refund monies will be dispatched to the applicants' addresses specified in their relevant application in the form of refund cheques in favour of the applicant (or, in the case of joint applications, the first-named applicant) by ordinary post on Monday, November 9, 2026 at the applicants' own risk.

Part of the applicant's identification document number, or, if in the case of joint applicants, part of the identification document number of the first-named applicant, provided by the applicant(s) may be printed on the refund cheque, if any. Such data would also be transferred to a third party for refund purposes. Banks may require verification of an applicant's identification document number before encashment of the refund cheque. Inaccurate completion of an applicant's identification document number may invalidate or delay encashment of the refund cheque.

If you are applying through the HKSCC EIPO channel, you are advised to contact your broker or custodian for the arrangement for the refund of the application monies. Subject to the arrangement between you and your broker or custodian and the applicable laws and regulations in Hong Kong, your broker or custodian will arrange refund to your designated bank account.

NO ISSUE OF SHARE CERTIFICATES

The H Share certificates for the Offer Shares have not been issued as at the date of this announcement and will not be delivered to any applicants.

By Order of the Board
Ganzhou Hemay Pharmaceutical Co., Ltd.
Dr. Zhang Hesheng
Chairman of the Board and Executive Director

Hong Kong, November 4, 2026

As at the date of this announcement, the Board comprises Dr. Zhang Hesheng, Mr. Chen Yingwei and Dr. Huo Aihong as executive Directors; Mr. Zhang Guangneng as non-executive Director; and Mr. Shao Leilei, Dr. Yang Cheng and Ms. Jia Meng as independent non-executive Directors.